Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme Lemtrada’s Momentum Halts With FDA “Refuse-To File” Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

The company says a data formatting issue was the reason FDA declined to accept the supplemental application for alemtuzumab for relapsing multiple sclerosis.

You may also be interested in...



Celgene Joins Troubled MS Club With Refuse To File For Ozanimod From US FDA

Other multiple sclerosis contenders – including Sanofi's Lemtrada, Acorda's Ampyra, and Merck KgAA's cladribine – have also been RTFed. Question now for Celgene is how long the delay will be. 

Chelsea Vows To Resolve Latest Regulatory Woes With Northera Quickly

Technical deficiencies foil the resubmission of Chelsea Therapeutics’ Northera. The company thinks it can resolve the problems quickly and some analysts expect a relatively short delay of one or two months to the user fee date.

Sanofi’s Aubagio And Biogen Idec’s Tecfidera Make It A Good Day For MS Sufferers At EMA

The EMA’s CHMP has given the nod to Sanofi’s Aubagio and Biogen Idec’s Tecfidera for multiple sclerosis, setting the scene for a European three-way battle with Novartis’ Gilenya in the coming months.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS074564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel